MVP Act
Sen. Mullin Pushes Bipartisan MVP Act to Only Pay for Medicaid Drugs if They Actually Work
Stalled
No legislative action in over 90 days.
↔Companion bill: Rep. Guthrie Introduces MVP Act to Link Medicaid Drug Payments to Patient OutcomesLegislative Progress
Key Points
- This bill changes how Medicaid pays for very expensive medicines, like gene therapies. Instead of paying the full price upfront, the government would only pay the full amount if the medicine actually helps the patient get better.
- Drug companies would be allowed to offer different price options to the government, as long as they offer the same deal to every state. This makes it easier for states to set up deals where they get a refund or pay less if a treatment doesn't work as promised.
- The plan helps states afford miracle drugs that can have very high costs. It allows them to pay in installments over time, which helps keep state budgets stable while still getting patients the care they need.
- It changes legal rules to make sure these performance-based refunds are allowed. This removes the risk of drug companies being accused of illegal kickbacks when they give money back to the government for a treatment that didn't help the patient.
- A non-partisan government office will study the program by June 2029 to see if it helps patients get rare disease treatments and if it actually saves money for the states.
Impact Analysis
Personal Impact
Life & Work
Smaller pharmaceutical and biotech companies developing expensive gene therapies or specialty drugs could benefit from clearer rules around value-based deals. The anti-kickback safe harbor removes legal uncertainty that has discouraged companies from offering outcome-based refunds to states, making it easier for innovative drug makers to bring products to market with flexible pricing.
Programs
Disabilities
Milestones
Read twice and referred to the Committee on Finance.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
3 articlesCongress is About to Overhaul the Drug Market. Consumers May Never Feel It.
As Congress nears a major overhaul of prescription drug pricing, the bipartisan MVP Act remains a central pillar. The bill aims to modernize Medicaid by allowing states to pay for high-cost gene therapies based on patient outcomes, though critics worry the savings may not reach consumers.
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
The Medicaid Value-Based Purchasing for Patients (MVP) Act is a top legislative priority for 2025. The bill seeks to codify 'multiple best price' rules, enabling Medicaid programs to enter into outcomes-based agreements for expensive cell and gene therapies without triggering price distortions.
Dems clash over drug price changes to Medicaid
House Democrats are divided over the MVP Act, which expands states' ability to pay for drugs based on patient outcomes. While supporters like Rep. Anna Eshoo argue it increases access to cures for sickle cell disease, others question if it aligns with broader drug pricing reform goals.
Source Information
Document Type
Congressional Bill
Official Title
MVP Act
Data Sources
Sponsor
Cosponsors
(2)Analysis generated by AI. Always verify with official sources.